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ABSTRACT 
 
 
THE ASSOCIATEION BETWEEN T CELL-RELATED GENE EXPRESSION AND 
FIBROSIS PROGRESSION IN RECURRENT HCV DISEASE 
 
By Alexander A. Philip, M.P.H. 
 
A thesis submitted in partial fulfillment of the requirements for the degree of 
Master of Science at Virginia Commonwealth University. 
 
   Virginia Commonwealth University, 2011 
 
Thesis Director: Valeria Mas, Ph. D., Associate Professor of Surgery and 
Pathology, Division of Transplant in the Department of Surgery 
 
 
Hepatitis C virus (HCV) is the major cause of chronic hepatitis worldwide 
and a leading cause for liver transplant. Unfortunately, graft HCV infection is a 
universal phenomenon despite of pre-transplant prophylactic strategies. Acute 
HCV infection and innate immune responses elicit an inflammatory scenario that 
triggers the recruitment of adaptive immune response cells. Of those chronically 
infected, 30% experience accelerated fibrosis with concomitant cirrhosis 
development within 5 years post-LT and require re-transplant. With many 
patients responding unfavorably to antivirals and ineffective vaccines, much 
attention is now placed on T cell immunity in controlling HCV infection. 
This study represents a retrospective analysis that examined the 
association of T cells with respect to liver fibrosis severity progression in a 
prospective cohort of biopsy samples taken from 27 patients at the time of HCV 
recurrence disease diagnosis post-LT. For those patients, the fibrosis 
progression was scored 36 months post-LT by Metavir scoring system. Liver 
biopsies were classified based on fibrosis severity as Mild (G1; n = 12), Moderate 
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(G2; n = 6), and Severe (G3; n = 9). Additionally, an independent set of liver 
biopsy samples, taken according to fibrosis severity progression, was classified 
(G1; n =3, G3; n = 4) and used as a validation set for CD4 gene expression. 
Real time PCR was performed to study the expression of immune-related 
genes using the Taqman® probe system. From the results analysis, the CD4 T 
cell marker encoding gene was down-regulated (2.9-fold) in G3 with respect to 
G1; although, only borderline significant (p = 0.052). This suggests an inverse 
relationship of CD4+T cell related-genes expression with respect to worse 
fibrosis progression in HCV recurrence diagnosed recipients. The validation 
samples showed a similar trend (1.8 fold decrease in G3 with respect to G1), 
although not significant. This may be due to impaired T cell function resulting 
from T cell exhaustion, poor dendritic cell priming and activation, or the use of 
immunosuppressant drugs. To conclude, CD4 could be a potential biomarker to 
help in identifying HCV recurrent patients with a high risk of fibrosis development 
soon after LT. 
 
 
 
 
 
 
 
 
 
 
 !
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Introduction 
 
Hepatitis C is an infectious liver disease that affects more than 170 million 
people worldwide (1). Within etiological agents, Hepatitis C virus (HCV) 
represents the major cause of the disease in US and Europe (2,3). Hepatitis is a 
medical condition that is defined by inflammation and swelling of the liver, and 
characterized by the presence inflammatory cells within the organ. The length of 
HCV infection varies. Few individuals with acute HCV infection (infection within 
the first 6 months) will clear the virus spontaneously, whereas the majority will 
develop long-term chronic HCV infection. This can progress to scarring of the 
liver (fibrosis) and may lead to liver failure. Hepatic fibrosis development is the 
main complication of HCV infection and results from an inflammatory scenario 
that triggers the production of cytokines and the induction of fibrogenesis. This 
can further progress to disease state known as cirrhosis and also hepatocellular 
carcinoma (4-7).  
Orthotopic liver transplantation (OLT) represents the optimal treatment for 
HCV-chronically infected patients diagnosed with end-stage liver disease due to 
cirrhosis in the USA, Europe, and Japan (7). Unfortunately, HCV recurrence 
disease due to virus re-infection of the graft constitutes a nearly universal 
phenomenon.  The disease recurrence is associated with graft damage, but 
interestingly the disease progression has been documented as variable among 
recipients. In this sense, 30% of patients experience accelerated fibrosis 
progression and cirrhosis development 5-years post-LT with the concomitant 
needs of liver re-transplantation (7).  
! "!
Organ availability constitutes an added important issue. Because there is 
an already limited supply of organs available, it is a nearly impossible task to 
keep supplying new livers to patients in need (7). Furthermore, there is no 
vaccine for HCV, and only about 50% of chronically infected patients respond 
favorably to antiviral treatment (combination interferon and ribavirin) (7). With all 
these factors taken into account, it is expected that the death rate from HCV 
infection will surpass that of AIDS by the turn of the 21st century (2,4-6). 
Therefore, since fibrosis development is the main complication of chronic HCV 
infection, it is of critical importance to understand disease progression and to find 
new ways to predict patients at increased risk for fibrosis development.  
 
 
 
 
 
 
 
 
 
 
 
 
 
! "!
The Hepatitis C Virus 
 
Hepatitis C virus (HCV) is an enveloped, single-stranded, positive sense 
RNA virus that belongs to the genus Hepacivirus within the family Flaviviridae (7-
10). Because HCV is an RNA virus, it lacks efficient proofreading mechanisms 
during replication. This allows for the virus to be highly mutable and has led to 
the rise of various virus quasispecies (4). Phylogenetic analysis has identified 
multiple HCV genotypes that have been classified into six groups or clades, with 
more than 100 subgroups or subclades within each group (2, 6, 10). This 
constant and rapid mutation of the viral genome (specifically the hypervariable 
region coding for the envelope proteins) is believed to allow the virus to escape 
immunological detection and elimination by the host (4).  
The only known natural host of the HCV virus is humans, with over 170 
million affected worldwide (6). This makes the HCV a major global public health 
problem. It is a blood borne pathogen that primarily replicates within the 
hepatocytes of the liver (4). The virus itself is comprised of a 9.6 kb, single-
stranded RNA (ssRNA) molecule which consists of a single open reading frame. 
This codes for a large poly-protein, which is later cleaved into individual proteins. 
The ssRNA molecule is surrounded by an icosahedral protective core (30-35nm) 
that is further encapsulated in a glycoprotein rich envelope (55-65nm) (11,12).  
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HCV and the Liver 
 
The primary site of HCV replication and disease progression is the liver. It 
is the largest organ in the body and performs over 500 vital processes, which 
include excretory functions, detoxification, and various metabolic functions. 
These functions are performed by the working cells of liver, called hepatocytes. 
Hepatocytes have the unique capacity to reproduce in response to liver injury. 
However, despite the liver’s remarkable ability to repair and recover after injury, 
repetitive insults can lead to liver failure, such as seen in HCV infection (6, 13).  
In addition to its various functions, the liver is also considered an intrinsic 
lymphoid organ (14). It contains a unique microenvironment that allows for the 
development and differentiation of immune cells distinct from those in the 
periphery. Studies have indicated that naïve T cells in the liver undergoing 
primary activation exhibited defective cytotoxic function, shortened half-life, and 
were not able to mediate hepatocellular injury; whereas, naïve T cells activated 
within the lymph nodes were capable of mediating HCV (15). It is unclear why the 
liver demonstrates intrahepatic tolerance, but it is believed that the constant 
presence of non-self antigens from incoming blood, directed from the intestines, 
has resulted in a tolerant environment (16). However, this constraint on liver 
immunity does not prevent the immune system from mounting a vigorous 
response against liver specific pathogens such as HCV (17). Of those acutely 
infected with HCV, 20% will resolve the virus spontaneously, while the majority 
will develop chronic hepatitis that may lead to end-stage liver disease (3,18).  
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The Innate Immune Response to HCV 
 
HCV progresses to chronic hepatitis in 50-80% of cases; however, a small 
fraction of those infected (20-50%) will spontaneously clear the virus (3,7). This 
indicates the immune system’s ability to control and clear HCV. Similar results 
were seen when study performed on persistent intravenous drug users showed 
that users who resolved previous HCV infections were 12 times less likely to be 
re-infected and to develop chronic infection. Those who were re-infected 
demonstrated HCV RNA levels two logs lower than people who were infected for 
the first time and developed chronic infection. These findings suggest that 
protective immunity does exist against HCV (18). The mechanisms underlying 
the different outcomes of HCV clearance is not clearly understood; however, it is 
clear that the innate immune response plays a key role in determining the 
outcome of viral infection and the extent of hepatic injury due to HCV 
by regulating adaptive immune response T cells (19).  
Two specific cell types of the innate immune system – dendritic cells and 
natural killer cells – are known to aid in the control and clearance of HCV by 
aiding in the development and differentiation of T cells into functional memory 
and effector cells. Studies indicate that HCV may affect both types of cells, which 
in turn, could affect T cell activation (Figure 1).  
T cell development is modulated by a group of antigen presenting cells 
(APC) known as dendritic cells (DC). DCs play a crucial role in the processing 
and presenting of antigens to initiate B and T cell responses, and also in 
! "!
tolerizing T cells to self-antigens. Both these roles are related to the maturity of 
DCs and their cytokine production patterns. Hence, DC function is precisely 
controlled to activate or tolerize T cells, and any perturbation to this control can 
lead to impaired immunity (18, 20-22).  
In addition to the activation of the adaptive immune system, DCs 
(specifically plasmacytoid-derived dendritic cells) play an important role in 
antiviral immunity through the production of type 1 interferons (IFNs). IFNs, such 
as IFN-alpha, are not only antiviral cytokines, but also important modulators of 
the adaptive immune response. It is reported that IFN-alpha enhances both the 
effector functions of T cells and the expression of proteins involved in viral 
antigen presentation. It also plays a role in the clonal expansion and 
differentiation of CD8+ T cells (18, 23-25).  
In vitro studies suggest that HCV infects both mature and monocyte-
derived DCs, which may lead to the dysfunction of DCs and altered adaptive 
immune response signaling. These include reduced production of IFN-alpha, 
impaired allo-stimulatory abilities to CD4+ T cells, and impaired secretion of IL-
12, an important cytokine that aids in the development of CD4+ T cell responses 
(26-30). Furthermore, chronic HCV infection is associated with a decrease of 
DCs in peripheral blood. These findings indicate that persistent HCV-infection 
may be due to a defective adaptive immune response mediated by HCV-induced 
DC dysfunction. Still, the exact role DCs play in HCV-specific immunodeficiency 
is unclear (18,31).  
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Another group of innate immune cells that plays an important role HCV 
control and clearance are natural killer (NK) cells. These aggressive lymphocytes 
are commonly found in the liver and play a critical role in the destruction of virally 
infected cells by directly inducing programmed cell death in the infected cell. NK 
cells also play an important role in immunoregulation by crosstalking with 
dendritic cells. NK cells and DCs reciprocally activate each other in a complex 
receptor/ligand pair reaction. This indicates the important role NK cells have in 
regulating the adaptive immune system against infections (32).  
Given the role NK cells have in activating DCs, it is believed that the 
modulation of NK cells could be another potential pathway for HCV to affect the 
innate and adaptive immune system. In vitro studies of HCV-infected patients 
demonstrated that NK cells overexpressed inhibitory receptors and produced 
cytokines that are known to attenuate the adaptive immune response (2). Still, it 
is unknown whether or not HCV affects NK cell activity in vivo. 
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The Adaptive Immune Response 
 
The adaptive immune system functions by targeting and destroying 
invading pathogens and the toxins they produce (33).  Unlike the innate immune 
system, it is highly specific against the pathogen that induced it, and can provide 
long-lasting protection (33). One major class of the adaptive immune system is 
the cellular mediated response, which is comprised of a group of lymphocytes 
called T cells. Different subsets of T cells play various roles in pathogenic control 
and clearance. Two well-known T cell types are CD8+ cytoxic T cells and CD4+ 
helper T cells. CD8+ cytotoxic T cells induce cell death on virally infected cells. 
CD4+ helper cells have no cytotoxic or phagocytic activity, but instead work by 
maximizing the capabilities of other immune cells and directing them to control 
and clear infected cells or pathogens (34). 
Studies of self-resolving HCV infection indicate a strong, HCV-specific 
CD4+ T cell response that was detected early during the acute phase and 
sustained for many years after clearance of HCV (35-38). In contrast, patients 
with chronic HCV infection demonstrated weak or absent T cell responses 
against chronic HCV infection as indicated by low T cell frequencies, short-lived 
responses, and defects in effector functions of specific T cells (39-44). Together, 
these studies strongly confirm the critical role T cells play in HCV infection.  
It is still unclear as to why T cell immune response fails to clear HCV 
infection in 50-80% of cases; however, additional studies that compared HCV to 
other persistent viruses (HIV, EBV, and CMV) presented interesting findings. 
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Results indicated that HCV specific CD8+ T cells, in peripheral blood, presented 
markers associated with an early differentiation phenotype, similar to resting 
influenza A virus-specific memory T cells which had not been exposed to the 
virus since the clearance of the last acute case of influenza.  Thus, HCV specific 
CD8+ T cells (in vivo) in patients appear to be in a dormant state, ignoring the 
HCV virus. Other studies of patients co-infected with both HCV and CMV 
suggested that a decline in CD8+ T cells in HCV infected patients result from the 
early loss of mature T cells, or through the impairment or regulation of T cell 
stimulation (19,45).   
 
 
Figure 1: Potential mechanisms for which HCV can interfere with the activation of the 
adaptive immune system. Studies suggest that HCV may affect the adaptive immune 
system by modulating NK cells, DCs, and T cells. 
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HCV Life Cycle 
 
HCV is primarily transmitted by blood, mostly through the use of 
intravenous drugs and blood transfusions (6).  Though the lifecycle of HCV is 
only partially understood, there is a general understanding of the virus’ lifecycle.  
The entry of HCV is triggered by a felicitously coordinated interaction between 
cell surface receptors and viral particles (46) (Figure 2). Though the exact 
process is not fully understood, it is believed that entrance into the hepatocyte 
requires tetraspanin CD81 (2), the scavenger receptor class B type 1 (47), and 
tight junction proteins claudin and occludin (48-50).  In addition, envelope 
glycoprotein complexes E1 and E2 located on the surface of the virus bind to 
LDL and VLDL surface receptors of hepatocytes, aiding in clathrin receptor-
mediated endocytosis and release of the viral capsid into the cytoplasm of the 
cell (6).  
Figure 2: HCV receptor mediated endocytosis into hepatocyte.  
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HCV does not enter the nucleus; rather, it stays in the cytoplasm where its 
ssRNA serves as mRNA for HCV protein synthesis and a template for viral 
replication (6).  HCV ssRNA consists of a single open reading frame that codes 
for a large poly-protein (3,000 amino acids) that undergoes co and post-
translation cleavage by both viral and host proteases located in the endoplasmic 
reticulum to yield ten separate and mature viral proteins (Figure 3) (2,4).  
 
 
Figure 3: HCV genome organization. HCV comprises of a 9.6 kb, single-stranded RNA 
molecule which consists of a single open reading frame. It codes for a large poly-protein, 
which is later cleaved into individual proteins that can be classified into 2 groups – 
structural proteins and non-structural proteins. 
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These ten proteins can be further classified into two groups: structural and 
nonstructural (NS) proteins. The structural proteins consist of Envelope 1 and 2 
(E1 and E2), Core, and p7 proteins. E1 and E2 heterodimerize to form the 
glycoprotein envelope which encapsulates the nucleocapsid, which itself is 
composed core proteins. P7 is believed to form an ion channel that allows the 
release and maturation of viral particles. The nonstructural proteins are believed 
to play a role in the pathogenesis of HCV infection and related liver disease by 
assisting in viral replication (6). They consist of NS2, NS3, NS4A, NS4B, NS5A, 
and NS5B (6). NS2, NS3, and NS4A are involved in the processing of the 
presumed NS region of the polyprotein (4). NS3 functions as both a helicase and 
a proteolytic cleavage enzyme, while NS5b is a RNA dependent RNA 
polymerase needed for viral replication that is regulated by NS5a (4, 6). Although 
there is a general understanding of the role and function of structural and 
nonstructural proteins, further research is yet to conclude the exact role these 
proteins play in the pathogenesis of HCV infection (6).   
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HCV pathophysiology 
 
Acute infection by HCV is uneventful in most cases due to the paucity of 
early symptoms, but runs a chronic course in an estimated 50-80% of patients (7, 
51). Chronic hepatitis results in liver damage, leading to inflammation, the onset 
of fibrosis, and the progression to cirrhosis in 10-20% of cases after 10 - 20 years 
post infection (Figure 4) (6, 7).  
 
 
Figure 4: Liver degeneration due to HCV infection. 80% of patients infected with HCV will 
develop chronic infection. Of those, 10-20% will develop cirrhosis within  10-20 years.   
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The exact mechanisms behind the onset and progression of hepatic 
degeneration are not fully understood; however, it is clear that the onset and 
progression of hepatic lesions is a result of the host immune response (6).  HCV 
infects hepatocytes and leads to their destruction. Whether the virus is cytopathic 
or not remains questionable.  What is known is that persistent hepatocyte death 
leads to the production cytokines/chemokines and growth factors (6, 13). This 
triggers the recruitment of inflammatory cells, which includes neutrophils, 
dendritic cells, natural killer (NK) cells, eosinophils, basophils, macrophages, and 
by residential macrophages called Kupffer cells, to the liver. Macrophages and 
NK cells synthesize and produce the pro-inflammatory cytokines TNF-alpha and 
IFN-gamma, which leads to the altered expression of cell adhesion molecules on 
sinusoidal endothelial cells and allows for further recruitment and chemotaxis of 
inflammatory cells. Regardless of noxae, these immune cells try to eliminate 
virally infected cells by inducing apoptosis, which leads to even more tissue 
damage (6,13). 
In response to tissue damage caused by both HCV and host immune 
response, hepatic stellate cells initiate the wound-healing process through a 
dynamic process known as fibrogenesis. The production of proinflammatory 
cytokines activates hepatic stellate cells (HSCs) to produce platelet derived 
growth factor (PDGF) and interferon growth factor 1 (IFG-1), leading to the trans-
differentiation and proliferation of myofibroblasts (MFBs).  In addition, HCV core 
and NS5a proteins alter signal transduction pathways in hepatocytes leading to 
the production of profibrogenic mediator TGF-B1, which has a predominant role 
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in the conversion of HSCs to MFBs. TGF-B, the most potent known inducer of 
fibrogenesis in hepatic stellate cells, stimulates the synthesis of extracellular 
matrix (ECM) proteins and also inhibits its degradation (13). ECM proteins 
consist mainly of collagen, but also laminin, fibronectin, and proteoglycans (6). 
Under most homeostatic circumstances within the body, fibrogenesis is balanced 
with fibrolysis; however, because of constant tissue damage by the host immune 
response to HCV, fibrogenesis dominates over fibrolysis, leading to the excess 
synthesis and deposition of ECM proteins in the liver (6, 13). This “scarring” 
process leads to the involvement of neighboring mesenchymal structures and the 
formation of fibrous septa and is called fibrosis. 
Fibrosis is the abnormal accumulation of ECM proteins in the liver, and is 
the main complication of chronic HCV infection. It is unclear what role viral 
factors play in the progression of fibrosis; however, exogenous factors seem to 
play a significant role. Immunodepressive factors such as co-infection of HIV and 
other hepatitis viruses and chronic injury from moderate alcohol consumption, 
obesity and diabetes (6, 13) seem to play a role in progression of fibrosis to a 
disease state known as cirrhosis.  
Cirrhosis is characterized by hepatocellular dysfunction and increased 
intrahepatic portal blood pressure due to diffuse fibrosis, parenchymal necrosis, 
and nodular regeneration of hepatocytes (4). It is at this point that the liver fails to 
function properly, and the patient needs a liver transplant.  
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HCV treatment 
 
Currently, no vaccine exists for HCV infection. This is because HCV 
comes in many forms and is constantly mutating to form different quasi-species. 
This highly mutable nature of HCV makes it difficult to manufacture antibody-
based vaccines (2,52-54). Current treatment for HCV is antiviral therapy, which 
consists of a combination of pegylated interferon (IFN) alpha and ribavirin (6). 
Ribavirin is a guanosine analog that is believed to increase IFNs effect and 
prevent late relapse by increasing the mutation rate of HCV toward “error 
catastrophe” (6). Though these treatments have proven successful against 
certain genotypes of HCV, liver transplantation (LT) is the principal surgical 
procedure recommended for treatment of Chronic HCV patients (7). After 
transplantation, many patients undergo prophylactic interferon based antiviral 
therapy to prevent graft infection and fibrosis development. Unfortunately, this 
treatment option has shown low response rates and high rates of adverse 
affects, hence there is an almost universal recurrence of HCV infection (7). 
Treatment for recurrent HCV infection is a combination of pegylated interferon 
and ribavirin, which has shown a 10-59% sustained virological response (7). 
Though HCV treatment has shown to be effective in controlling inflammation after 
viral eradication, fibrosis regression or stabilization has proven to be less 
predictable (7).  
In addition to antiviral therapy, patients who undergo OLT must also 
receive immunosuppressive therapy to prevent graft rejection by the host. 
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Currently, there are many immunosuppressive treatments available to patients 
undergoing OLT, these include calcineurin inhibitors (CNI), corticosteroids, 
antimetabolites, and antibody therapy (55). CNIs inhibit T cell activation by 
binding to calcineurin, a calmodulin dependent phosphatase that plays a critical 
role in transcription and activation of T cell cytokines, including IL2 (55).  
Similarly, Corticosteroids work by blocking T cell-derived and APC-derived 
cytokine expression, which includes IL1, IL2, IL3, and IL6. Antimetabolites 
function by inhibiting RNA, DNA, and protein synthesis, either by antagonizing 
purine and pyrimidine nucleotide metabolism. This results in the blockage of DNA 
replication in T lymphocytes (55). Lastly, antibody therapy works by targeting 
multiple different epitopes on T cells and APCs with monoclonal antibodies. A 
common Anti-T cell antibody is OKT3, which binds to CD3 on the surface of T 
cells. This prevents the activation T cells and results in the decline of mature T 
cells (55).   
It is important to note that almost all immunosuppressive therapies work 
by depleting or hindering T cells, which are known to play a critical role in 
resolving acute HCV infection. However, if T cell activity is not controlled, the 
host will reject the new graft. Hence a delicate balance of antiviral and 
immunosuppressant therapies must be administered to patients to allow for both 
graft survival and viremic control.  
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Post-liver transplantation disease progression 
 
HCV-related end-stage liver disease constitutes the leading indication for 
orthotopic liver transplantation (LT) in the USA, Europe and Japan. After OLT, 
there is a universal recurrence of HCV infection in virtually all patients at the time 
of reperfusion (7). After week 2 post-LT, serum HCV RNA levels increase rapidly 
and peak around 1 to 3 months. Within a year, HCV viremia plateaus at 1-2 logs 
higher than pre-LT levels (7). Even with antiviral treatment (combination 
pegylated interferon and ribavirin), approximately one-third of patients will 
develop accelerated fibrogenesis, which will progress to severe fibrosis (stage > 
3) at 5 years post-LT.  Hence, approximately 10-25% of HCV recurrent patients 
will die or require retransplantation within 5 years post-LT (7) (Figure 5). 
However, very few patients will undergo retransplantation, subsequently because 
many centers are reluctant to relist patients with previous graft failure due to HCV 
recurrence (51). Patients that are relisted experience a high wait list mortality 
(50-80%) due to rapid deterioration following liver decompensation (51,56).  
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Figure 5: HCV disease progression pre-LT and post-LT. Post-LT disease progression 
resembles that of Pre-LT disease progression, except at a more rapid pace. 
 
 
Though the understanding of HCV has steadily progressed in the last few 
decades, little is still known regarding specific pathogenesis in recurrent HCV 
infection. What is known is that the immune response in recurrent chronic HCV 
infection resembles that of chronic HCV infection in immunocompetent patients, 
except at a more rapid pace (6,13).  The Immune response against recurrent 
HCV infection is characterized by activation of the innate immune system and the 
recruitment of the adaptive immune response cells (57-58). These consist of T 
lymphocytes (particularly regulatory T cells, cytotoxic T cells, T helper cells) and 
also B cells. Significant research in the last ten years has shown the importance 
of the adaptive immune response in controlling HCV disease progression. CD4+ 
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T cells have been linked to the control and clearance in acute HCV infection and 
also a protective effect against progressing liver disease in chronic HCV infection 
(18).  
The fibrosis progression severity in HCV recurrence disease is variable. 
The molecular mechanisms involved in accelerated fibrogenesis progression in 
HCV-infected recipients have been recently studied (59).  However, despite the 
well-known presence of T cells infiltrates into the new graft, considerable gaps 
still exist in our understanding of the role the adaptive immune response plays in 
severe fibrogenesis progression in HCV recurrence. 
With more than 2,000 liver transplants done every year in the United 
States due to HCV alone, combined with the significant rise in cirrhosis 
development in untreated HCV patients and an already limited supply of organs, 
there is an almost impossible burden of supplying patients with new livers (7). 
Because of this, it is of utmost importance to understand the role the adaptive 
immune response plays in the progression of fibrosis, the main complication of 
HCV infection, and to investigate biomarkers that may help predict and prevent 
severe fibrosis progression in HCV recurrent patients.  
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Study rationale: Preliminary data conducting the present research: 
Molecular analysis of HCV recurrence disease 
 
Previously in our lab, we studied the molecular biology of HCV recurrence 
using microarray technology in frozen liver biopsy samples. From these 
preliminary results, a pairwise comparison analysis of normal and HCV re-
infected grafts was performed to identify molecular pathways involved in HCV 
recurrence. Gene ontology analysis identified T lymphocytes (CD4+ and CD8+) 
Antigen Presentation Signaling cascade as the top canonical pathway (Figure 6). 
Cytotoxic T Lymphocyte-mediated Apoptosis of Target Cells pathway were also 
identified. These results are in accordance with previous reports demonstrating 
high T cell-mediated immune response in HCV recurrence disease (60,61).  
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Figure 6: Antigen presentation canonical pathway. Oval shapes in color represent 
differentially expressed genes in HCV recurrence disease versus normal allograft. Red ovals: up-
regulation; Green ovals: down-regulation. The color intensity indicates the gene deregulation 
level. Total RNA was extracted from frozen tissue samples using Trizol following manufacturer’s 
protocol. RNA quality control criteria included: 28S/18S ratios >1.5, A260/A280 ratios of 1.9-2.1, 
and RIN !7. Microarray generation and analysis: Labeled cRNA synthesis, in vitro transcription, 
chemical fragmentation, and hybridization cocktail preparation for HG-U133A v2.0 GeneChips® 
(Affymetrix) were performed according to the manufacturer protocol. Microarray image was 
generated using high-resolution Affymetrix GeneChip Scanner 3000. Data were analyzed with 
Affymetrix Microarray Suite Software v5.0 and Bioconductor packages (70, 71). Sample groups 
were compared using moderated t-test with Holm's method. A p-value " 0.05 was considered 
significant. Ingenuity Pathway Analysis tool v8.6 (www.ingenuity.com) was adopted for gene 
ontology and gene interaction analysis.  
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Hypothesis and Aims 
 
Our current study intends to identify T cell related genes in varying levels 
of fibrosis progression in post-LT, HCV recurrent patients, as well as other 
various immune cells that have been known to play a role in viral clearance.  
Graft injury in HCV recurrence disease arises as a result of the immune 
response to control the acute HCV infection and disease progression. It is 
characterized by activation of the innate immune system and the recruitment of 
the adaptive immune response cells (13, 62). Thus, it is hypothesized that the 
elucidation of the early immune response involved in the liver graft at the time of 
HCV recurrence might help to identify those patients with high risk of fibrosis 
development at early post-liver transplantation stage. 
Though studies have been done on T cell markers in HCV recurrent patients 
with differential fibrosis, this will be the first retrospective study, to the best of our 
knowledge, aimed to predict accelerated hepatic fibrogenesis in HCV recurrent 
patients based on the expression of certain adaptive immune cells, particularly T 
cells, at the time of HCV recurrence. In this project, we aimed: 
! To examine the association of expression of T cell genes at the time of HCV 
recurrence and the severity of liver fibrosis progression in the new graft 
! To identify the immune cells that associate with accelerated fibrogenesis 
post-liver transplantation 
! To validate these results using an independent set of samples 
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Methods and Materials 
 
Study Design  
 
In this study, T cell gene expression analysis, using QPCR, was done on 
RNA isolated from FFPE biopsy samples (n = 27) taken at the time of HCV 
recurrence. Biopsy samples taken at 36 months post-LT were assessed for 
fibrosis progression using Metavir scoring. The expression level of those genes 
was analyzed with respect to the fibrosis grade assessed at 36 months post-LT 
in order to predict accelerated hepatic fibrogenesis events in response to HCV 
recurrence disease. For our validation study, T cell gene expression analysis was 
also done on RNA isolated from frozen tissue biopsy samples (n = 7) taken 
based on fibrosis severity progression. A flow chart indicating our study can be 
seen in figure 9, below.  
Figure 9: Study design flow chart.  
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Samples and Patients 
 
The Institutional Review Board at the Favaloro Foundation (Buenos Aires, 
Argentina) and Virginia Commonwealth University has approved the study 
protocol. The study included 27 adults who underwent OLT for HCV induced 
cirrhosis at the Favaloro Foundation (Buenos Aires, Argentina) between 1995 
and 2006. All patients completed at least 3 years of follow-up post-OLT and 
underwent liver biopsy at that time of clinical HCV recurrence, defined by 
increased ALT level and positive HCV viremia, and at 36 month post-OLT for 
liver fibrosis progression assessment as marker of recurrent disease severity. 
Furthermore, an independent set of 8 patients who underwent OLT for HCV 
induced cirrhosis at Hume-Lee Transplant Center at Virginia Commonwealth 
University were also evaluated as a validation set.  
Patient enrollment considered and collected: 1) Medical history, 2) 
Demographic information (age, gender, race, duration of HCV infection, alcohol, 
use of intravenous drugs, genetic factors (i.e., HLA), diabetes), 3) HCV RNA 
quantitative assay, 4) HCV genotype. 
Patient inclusion criteria consisted of: 1) Age: >21-<70 years old, 2) 
Patients listed for OLT, 3) Anti-HCV positive and HCV RNA positive in serum 
prior to and after undergoing OLT, 4) HCV recipients without HCV treatment 
post-OLT are included in the study (to assure evaluation of natural HCV 
progression post-OLT). On the other hand, patients were excluded by: 1) Re-
transplantation (any cause) and/or multiple-organ transplantation, 2) HCV RNA 
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not done or undetectable prior OLT, 3) Pre-operative diagnosis of fulminant 
hepatitis, cryptogenic cirrhosis, primary billiary cirrhosis, primary sclerosing 
cholangitis, autoimmune hepatitis, or metabolic liver diseases, 4) Recipient of 
anti-HCV positive organ, 5) Co-diagnosed chronic hepatitis B and/or HIV, 6) 
Pregnancy, 7) HCV RNA repeatedly negative (by PCR) post-OLT, 8) Presence of 
acute rejection in the allograft biopsy (by clinical and histological criteria) at the 
time of clinical HCV recurrence (as defined by detectable HCV RNA in serum 
and elevated ALT), 9) Vascular and biliary complications post-OLT resulting in 
the need for interventions. 
Post-OLT immunosuppression consisted of calcineurin inhibitors 
[cyclosporine A and tacrolimus] and corticosteroids. Certain patients received 
induction therapy [OKT3, anti-thymocyte globulin, or basiliximab], and some 
received a third immunosuppressive agent at some time during follow- up 
[mycophenolate or azathioprine]. Patients with biopsy-proven acute rejection 
received 1 intravenous bolus of 1 g of methylprednisolone, which was followed 
by an oral recycle of prednisone with a starting dose of 200 mg/day. 
Postoperatively, all patients underwent clinical and biochemical monitoring at 
regular but variable intervals (biweekly, weekly, every other week, and monthly 
thereafter) according to individual outcomes.  In order to provide a natural way of 
infection, no patient received antiviral therapy for HCV for the duration of the 
study.  
Patient information and laboratory results at pre and post-OLT times that 
have been prospectively collected were retrospectively evaluated. This includes: 
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Transplantation time assessments and data collection: 1) Clinical scores, 
Including the “model for end-stage liver disease” (MELD) score and Child-
Turcotte-Pugh (CTP) score (22), both methods used by United Network of Organ 
Sharing (UNOS) to select patients for transplantation 2) HCV viral load at 
transplantation time, 3) Donor demographic information (age, race, sex), donor 
cause of death, 4) Cold ischemia time, warm ischemia time, 5) Type of donor 
(deceased donor/liver donor), 6) Donor demographics and characteristics (age, 
race, gender, history of alcohol/drug abuse, cause of death) 7) HCV genotypes. 
 
Post-transplant assessments and data collection: 1) HCV viral load at week 
1, Month 3, Year 1, 2, and 3:  HCV RNA quantitative analysis, 2) FFPE liver 
biopsies at clinical HCV recurrence time or first protocol biopsy (6 months post-
OLT) (for molecular studies) and at 60 months post-OLT (for histological fibrosis 
score evaluation) (All the biopsy times are in concordance with our clinical biopsy 
protocol biopsy), 3) Histological evaluation of biopsies, 4) Immunosuppressive 
drugs monitoring, 5) Episodes of acute rejection, 6) Treatment of acute rejection, 
7) CMV infection, 8) Liver function panel: AST, ALT, total bilirubin, albumin, 
fibrinogen, and platelets at the biopsy times. 
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Liver biopsy samples 
 
Formalin-Fixed Paraffin-Embedded (FFPE) liver biopsies at the time of 
HCV recurrence diagnosis (in an average time of 6 months post-OLT) defined as 
increased alanine aminotransferase levels (ALT) and positive HCV viremia. A 
retrospective analysis on gene expression was conducted on these samples 
using QPCR based on the fibrosis progression of biopsy samples from the same 
patients taken 36 months post-LT. Frozen tissues sample biopsies were taken 
according to the severity of fibrosis progression post-LT. 
Biopsy samples were classified based on fibrosis progression using the 
METAVIR scoring system (Figure 7). This system has been specifically designed 
to assess fibrosis staging of fibrosis from biopsy samples taken from HCV-
infected patients (7). The level of fibrosis is graded on a 5-point scale from F0 to 
F4: F0 (absent), F1 (portal fibrosis), F2 (portal fibrosis with few septa), F3 (septal 
fibrosis), or F4 (cirrhosis).  
 
Figure 7: METAVIR score system used to assess fibrosis progression. 
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In addition, necroinflammation activity is graded as A0 (absent), A1 (mild), 
A2 (moderate), or A3 (severe). According to the severity of fibrosis progression 3 
years post-OLT, the patients were placed in three groups: (1) G1 for mild fibrosis 
(F0-F1), (2) G2 for moderate fibrosis (F2), and (3) G3 for severe fibrosis (F3-F4)  
(Figure 8). 
 
 
Figure 8: The classification of our samples into 3 groups (G1, G2, G3) based on fibrosis 
progression using METAVIR scoring. 
 
RNA Isolation 
 
Total RNA from FFPE samples was isolated using Recover All™ Total 
Nucleic Acid Isolation Kit (Ambion, Austin, TX, USA).  Briefly, FFPE samples 
were incubated in warm xylene in order to solubilize and remove the paraffin wax 
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from the tissue. Then, the deparaffinized samples are washed with alcohol to 
remove excess xylene, and then subjected to protease digestion. This removes 
any proteins that may be covalently bound to RNA. RNA is purified and captured 
by glass-fiber filtration, washing, and elution. Lastly, a series of high ethanol 
washes ensure the recovery of smaller RNA fragments.  
Total RNA from frozen tissue samples was extracted using TRIzol® (Life 
Technologies, Carlsbad, CA, USA) reagent following manufacturer’s protocol. 
TRIzol is a monophasic solution of phenol and guanidine isothiocyanate that 
maintains RNA integrity and assists in the disruption of cell membranes. RNA 
quality control criteria included: 28S/18S ratios >1.5, A260/A280 ratios of 1.9-2.1, 
and RIN !7. 
 
Quantitative Real time Polymerase Chain Reaction 
 
The expression of selected T cell-related genes was studied on both 
FFPE liver biopsies collected at the time of HCV recurrence disease diagnosis, 
and defined as the Training study group, and also on frozen tissue biopsies 
collected based on post-LT fibrosis severity as Validation group for the 
expression of CD4-encoding gene (see below). Relative gene expression levels 
was evaluated using Taqman!Gene expression Assays (Applied Biosystems). 
Gene quantitation assays were performed in a two-step real time PCR. The first 
step consists of reverse transcription of total RNA into cDNA. In the second step, 
PCR products are amplified and probed with specific fluorescent reporter dyes. 
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This allows for the simultaneous quantification and amplification of a target gene. 
Proposed target genes for expression evaluation were selected based on specific 
immune cells (Table 1).  
In an attempt to identify the presence of helper T cells, probes specific for 
helper T cell activation markers IL2 (Hs00174114_m1), IL4 (Hs00174122_m1), 
and IL17 (Hs00174383_m1), and cell surface marker CD4 (Hs00181217_m1) 
were used. To identify the presence of cytotoxic T cells, probes specific for 
cytotoxic T cell surface markers CD3 (Hs01062241_m1) and CD8 
(Hs00233520_m1) were used. To identify the presence of regulatory T cells, 
probes specific for regulatory T cell activation markers FOXP3 
(Hs01085834_m1), CTLA4 (Hs03044418_m1), LLRC32 (Hs00194136_m1), and 
TNSFR1 (Hs00188346_m1), as well as surface markers CD4 and CD25 
(Hs00907779_m1) were used. To identify B cells, a probe specific for common B 
cell surface marker CD19 (Hs00174333_m1) was used. In addition, IL28RA is a 
receptor subunit that is associated with viral infection, and its expression was 
also be analyzed. 
B2M gene was used as endogenous control for gene expression 
normalization. The expression level of selected T cell-related genes was 
analyzed with respect to the fibrosis grade assessed at 36 months post-LT used 
to predict accelerated hepatic fibrogenesis events in response to HCV recurrence 
disease.  
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Table 1: Immune cells and their corresponding target genes. * Indicates repeated gene CD4 
which was used as an identification marker for both Helper T cells and Regulatory T cells.  
 
 
 
 
 
 
 
 
 
 
!
Immune Cell Target Gene 
Helper T Cell 
CD4 (Hs00181217_m1): Surface Marker 
IL2 (Hs00174114_m1): Activation Marker/ Interleukin 
IL4 (Hs00174122_m1):  Activation Marker/ Interleukin 
IL17 (Hs00174383_m1):  Activation  Marker/ Interleukin 
Cytotoxic T Cell 
CD3 (Hs01062241_m1):  Surface Marker 
CD8 (Hs00233520_m1):  Surface Marker 
Regulatory T Cell 
CD4* (Hs00181217_m1):  Surface Marker 
CD25 (Hs00907779_m1):  Surface Marker 
FOXP3 (Hs01085834_m1):  Activation Marker/ Transcription factor 
CTLA4 (Hs03044418_m1):  Activation  Marker/ Cytokine 
TNSFR18 (Hs00188346_m1):  Activation  Marker/ TNF receptor 
B Cell CD19 (Hs00174333_m1):  Surface Marker 
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Data Analysis 
 
The expression level of these specific genes were analyzed with respect 
to the fibrosis grade assessed at 36 months post-LT, and aimed to predict 
accelerated hepatic fibrogenesis events in response to HCV recurrence disease. 
Relative gene expression levels were calculated using the !!Ct method and 
expressed as fold changes. Delta Ct value (!Ct) were obtained by normalizing 
the target gene Ct value with respect to the "2M gene as endogenous control 
(!Ct = target Ct – "2M Ct) for each sample. The average !Ct was calculated for 
each study group. Differential gene expression among groups was expressed as 
fold changes with respect to “Benign” fibrosis as 1. Thus, the !!Ct value was 
calculated for each group (!!Ct = !Ct G1,G2 or G3 - !Ct G1). Fold changes 
were calculated as 2-!!Ct. 
 
Statistical Analysis  
 
Patient data regarding clinical and pathological characteristics and 
was analyzed by chi_square statistic (X2, contingency tables) and Analysis of 
Variance (ANOVA). QPCR data for the three different subpopulations was 
analyzed using Analysis of Variance (ANOVA) and Tukey’s Honest Significant 
Difference Test. A p-value of <0.05 was considered significant.  
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Results  
 
 
T cell-related gene expression and its association with fibrosis progression 
severity were retrospectively evaluated in a prospective cohort study of 27 HCV-
infected recipients. In addition, a validation group constituted by 7 patients was 
also retrospectively evaluated. Gene expression was determined in biopsy 
samples taken at the time of HCV recurrence disease defined as increased ALT 
level and positive HCV viremia. The expression level of those genes was 
analyzed with respect to the fibrosis grade assessed at 36 months post-LT aimed 
to predict accelerated hepatic fibrogenesis events in response to HCV recurrence 
disease (Figure 10). 
 
 
Figure 10: Retrospective research study scheme. T-cell related gene analysis done on our 
patient population was used to possibly predict the severity of fibrosis progression.  
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Clinico-pathological characteristics of patient groups: 
 
Clinico-pathological parameters of HCV-positive recipients from FFPE 
samples are described in Table 2. No patients received antiviral therapy for HCV 
infection control during the study. Most of recipients were infected with HCV 
genotypes 1a/b (a = 4; b = 22). One patient was infected with HCV genotype 2a 
(Mild group). The mean HCV recurrence times were 5.8±5.0, 4.3±2.7, and 
4.1±2.0 months for Mild, Moderate and Severe fibrosis groups, respectively, 
without a significant difference among groups.  Out of the 27 patients in our 
study, 12, 6, and 9 patients were classified for having mild, moderate, and severe 
fibrosis development, respectfully, at 36 months post-LT. No significant 
differences were found among groups regarding age, gender, liver donor type, 
ALT blood levels, as well as administrated immunosuppressant type, acute 
rejection episodes, and treatment. Patients showed significant decreases in 
follow-up time post-LT as fibrosis severity worsened. This can be attributed to the 
fact that HCV recurrent patients with severe fibrosis experience higher mortality 
rates (7). This same trend can be seen in patient deaths, which significantly 
increased with fibrosis severity progression. Re-transplantation increased toward 
the development of severe fibrosis.  
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Table 2: Clinico-pathological parameters of HCV recurrence diagnosed patients (FFPE 
samples).  
 
 
 
 
Patient Group Mild Moderate Severe P value
Sample size (n) 12 6 9
Age in years (Interval) 51 (37 – 65) 53 (41 – 59) 57 (47 – 66) 0.51
Gender (M/F) (8/4) (2/4) (6/3) 0.34
HCV genotype 1/2-3 (11/1) (6/0) (9/0) 0.76
Liver donor 10 (83) 3 (50) 5 (56)
•Diseased (%) 2 (17) 3 (50) 4 (44) 0.25
•Living (%)
Time to recurrence in 
month
•<6 7 4 7 0.54
•6-12 2 2 1
•>12 ! " #
ALT at recurrence in IU/L 
(mean ± SD)
228 ± 118 221 ± 77 329 ± 192 0.22
Cyclosporine (%) / 
Tacrolimus
6 (50) / 6 3 (50) / 3 8 (89) / 1 0.14
Acute rejection (%) 5 (42) 2 (33) 4 (44) 0.90
Treated acute rejection (%) 4 (33) 2 (33) 4 (44) 0.85
Steroid boluses (%) 4 (33) 2 (33) 4 (44) 0.85
•1 Bolus 1 (25) 1 (50) 1 (25)
•2 Bolus 3 (75) 0 3 (75) 0.21
•3 Bolus 0 (0) 1 (50) 0 (0) 
Follow up post-LT in years 
(Interval)
10.0 (5 – 12) 7.0 (3 – 10) 6.8 (5 – 10) 0.03
Re-transplantation (%) 0 (0) 1 (17) 3 (33) 0.18
Death (%) 0 (0) 1 (17) 4 (44) 0.03
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Expression analysis of immune response-related genes: 
 
In order to identify and define the immune response, specific markers 
were selected for each immune cell subset. To identify helper T cells, the 
expression of those genes encoding CD4, IL2, IL4, and IL17 were determined by 
the analysis of transcript (mRNA) levels by qPCR. In a similar manner, cytotoxic 
T cells were evaluated through the CD3 and CD8-encoding gene expression 
analysis. Genes encoding for CD4, CD25, FOXP3, LLRC32, CTLA4, and 
TNFSR18 were analyzed to identify regulatory T cells. The B cells presence was 
evaluated by the CD19 encoding gene expression. Gene expression analysis for 
validation samples was performed only on CD4.  
PCR amplification was observed for CD4, IL28RA, CD8, FoxP3, LRRC32, 
and CD3 in 100%, 92%, 67%, 56%, 37% and 22% of samples, respectively 
(Table 3). In addition, any amplification signal was detected for IL2, IL4, IL17, 
CD19, CD25, CTLA4, and TNFRSF18 over all samples (Table 3).  
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Table 3: T cell-related gene expression analysis by sample groups. PCR amplification was 
observed in FFPE samples for CD4, IL28RA, CD8, FoxP3, LRRC32, and CD3 in 100%, 92%, 
67%, 56%, 37% and 22% of samples, respectively (table 3). All samples were negative for IL2, 
IL4, IL17, CD19, CD25, CTLA4, and TNFRSF18. (+) Indicates positive amplification, (-) indicates 
no amplification. 
 
 
Gene expression analysis of target genes for particular immune cells 
showed the following results: CD4 gene expression showed down regulation 
trend amongst the three groups (G1, G2, G3), however, this was borderline 
significant (using ANOVA test: p = 0.053) (Figure 11). A pairwise comparison 
was done between G3 (severe) vs. G1 (mild), and there was 2.9 fold down 
regulation that was also borderline significant (p = 0.052). Validation group 
Group Sample CD4
CD8 
(A) FoxP3
IL28R
A
LLRC3
2 CD3 CD25 CTLA4
TNFR
SF18 CD19 IL2 IL4 IL17
1 + + + + - + - - - - - - -
2 + + + + + - - - - - - - -
3 + - + + - - - - - - - - -
4 + - - - - - - - - - - - -
Mild 5 + + - + + - - - - - - - -
(n = 12) 6 + - - + - - - - - - - - -
7 + - + - - - - - - - - - -
8 + + + + + + - - - - - - -
9 + + + + - + - - - - - - -
10 + + + + + + - - - - - - -
11 + - - + - - - - - - - - -
12 + + - + - - - - - - - - -
13 + + - + - - - - - - - - -
14 + - + + - - - - - - - - -
Moderate 15 + - - + + - - - - - - - -
(n = 6) 16 + + - + + + - - - - - - -
17 + + - + + - - - - - - - -
18 + + - + - + - - - - - - -
19 + + - + - - - - - - - - -
20 + + - + - - - - - - - - -
21 + + + + - - - - - - - - -
Severe 22 + - + + - - - - - - - - -
(n = 9) 23 + + + + + - - - - - - - -
24 + + + + + - - - - - - - -
25 + - + + - - - - - - - - -
26 + + + + + - - - - - - - -
27 + + + + - - - - - - - - -
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samples presented a similar trend, with a 1.8-fold decrease CD4 expression 
between G3 vs. G1, although not significant. 
Similarly, FoxP3 expression decreased 3.1-fold in G3 with respect to G1, 
although these were not significant. LRRC32 expression also decreased in G3 
samples compared to G1. CD8 expression showed a 1.4 fold decrease between 
G3 vs. G1. CD3 expression showed a 0.6 fold decrease between G2 vs. G1, and 
no amplification in G3.   
 
  
 
 
Figure 11. CD4 Gene Expression Analysis. 
Gene expression is shown as fold changes referred to Mild fibrosis as 1. Fold change values are 
indicated below each bar. Patient groups named as the fibrosis severity grade are detailed in the 
X-axis. * Indicates that there was no significant decrease in CD4 amongst the three groups.  
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Validation Study Results  
 
  
 
To validate these results, the CD4 gene expression was validated in an 
independent set of HCV recurrence diagnosed patients with no fibrosis 
development (n = 3) and moderate to severe fibrosis development (n = 4). Liver 
biopsy samples were obtained from each patient and fibrosis progression was 
classified accordingly with Metavir scoring system as described previously. 
Clinico-pathological and demographic patients characteristics are described in 
Table 4. Briefly, patient age, gender, race, was taken into account, as well as 
cases of acute rejection, HCV recurrence, and Metavir score.  Total RNA was 
isolated from frozen liver biopsy samples (n = 7) as described in the Patients and 
Methods section. Following, the CD4 gene expression was analyzed using 
qPCR. From the results analysis, a specific and significant amplification was 
observed for CD4 in all analyzed samples. Interestingly, the CD4 expression was 
found to be 1.8 fold down-regulated between G3 (n = 4) and G1 (n= 3), although 
this differential expression was found to be not significant (Figure 12). 
Nevertheless, it is important to remark that the obtained results coincide with the 
CD4 expression levels observed in the training group of samples. Importantly, it 
permits postulate a negative regulation of the CD4 encoding gene in those HCV 
recurrence cases with severe fibrosis progression.   
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Table 4: Clinico-pathological parameters for frozen tissue samples used in 
validation study.  
 
 
Figure 12: CD4 Gene Expression Analysis for Validation Study. Fold change values 
are indicated below each bar. Patients groups named as the fibrosis severity grade are detailed in 
the X-axis.  
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Discussion 
 
HCV infection is a major public health concern, with over 170 million 
people around the world affected by the virus (7). Though the clinical course of 
HCV is highly variable, 85% will develop chronic infection, which is characterized 
by the development fibrosis, then cirrhosis, and then hepatocellular carcinoma. 
Because of this, HCV is the leading cause for liver transplant in Europe and the 
USA (7). Unfortunately, graft HCV infection is a universal phenomenon and is 
characterized by accelerated fibrosis progression and the development of 
cirrhosis within 5 years of transplantation in 30% of patients (7). With the 
increasing difficulty to produce long lasting and effective vaccines, combined with 
the failure of antivirals to successfully clear the virus, much attention is now 
focused on the adaptive immune system, particularly T cell immunity, in 
controlling HCV infection. In an attempt to better understand accelerated fibrosis 
development in HCV recurrence disease and find potential biomarkers, we 
investigated the presence of particular lymphocytes of the adaptive immune 
system.  
The adaptive immune system plays a significant role in determining the 
outcome of HCV infection. Both a strong CD8+ T cell response and a vigorous 
and sustained CD4+ T cell response can be seen in non-transplant patients who 
resolve acute HCV infection (63). However, in chronic HCV infection, CD4+ T cell 
responses are weak or absent, and have been linked to the development of 
fibrosis and cirrhosis (63). Similarly, a study on the peripheral blood of HCV 
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recurrent patients demonstrated detectable CD4+ specific T cell responses in 
patients with mild or no histological recurrence; whereas patients with severe 
histological recurrence were hyporesponsive to HCV antigens (64). Our findings 
are consistent with these concepts as our results show that patients with down 
regulated T cell-related genes at the time of HCV recurrence developed more 
severe fibrosis 36 months post-LT.  
In our analysis, T cell-related gene expression and its association with 
fibrosis progression severity were retrospectively evaluated in a prospective 
cohort study of 27 HCV-infected recipients. Gene expression was determined in 
biopsy samples taken at the time of HCV recurrence disease defined as 
increased ALT level and positive HCV viremia. The expression level of those 
genes was analyzed with respect to the fibrosis grade (Mild: G1, Moderate: G2, 
Severe: G3) from liver biopsies assessed at 36 months post-LT aimed to predict 
accelerated hepatic fibrogenesis events in response to HCV recurrence disease. 
Our study showed a 2.9-fold down-regulation of the CD4 gene in patients with 
severe fibrosis development (G3) with respect to patients with mild fibrosis (G1). 
Similarly, down regulation trends were also seen observed in cytotoxic T cell 
related genes (CD3 and CD8) as well as regulatory T cell-related genes (FOXP3, 
and LLRC32) in patients with severe fibrosis in respect to mild fibrosis; although, 
all of these were not significant.  
 The exact reasons underlying the weakened or absent T cell-mediated 
response in chronically HCV infected patients is unknown. One theory based on 
a study done on lymphocyte chloromeningitis virus (LCMV) suggests that HCV-
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specific T cells may experience “exhaustion.” The study showed that mice 
persistently infected with LCMV resulted in chronic T cell activation followed by 
sequential loss of T cell function (2). Likewise, chronic HCV infection has also 
been associated with continuous activation of HCV-specific T cells but with 
impaired function (65,66). Mice models affected with LCMV showed a decrease 
in IL2 production, followed by a loss of cytotoxicity, TNF-a production, and IFN-y 
production. These results not only coincide with previous studies that have 
shown impaired effector functions of CD4+ and CD8+ T cells in chronic HCV 
infection (51), but also with the results from our study. T cell exhaustion could 
provide the rationale for the down regulation of CD4 and CD8 genes and the lack 
of IL2 amplification in our study.  
Accumulating data also suggests that an absent T cell response in chronic 
HCV patients might be due to impaired dendritic cell function. Dendritic cells play 
a critical role in the priming and activation of T cells. Failure of DCs to activate T 
cells in chronic HCV infection could explain the down regulation of T cell-related 
genes in our study. Studies on peripheral blood DCs in chronic HCV infection 
demonstrated impaired ability of DCs to activate allogeneic T cells (40). The 
exact mechanism behind this is not fully understood, but this could be due to a 
lack in DC maturation. A study performed by Aufferman-Gretzinger (27) on the 
peripheral blood of patients who successfully resolved the HCV virus showed 
that monocyte-derived DCs from chronic HCV patients failed to respond to 
maturation stimuli. Unlike DCs from healthy donors, they failed to upregulate cell 
surface proteins for antigen presentation. Since mature DCs aid in the 
! "#!
development of naïve T cells to CD4+ TH1 cells and promote the maturation of 
cytotoxic T cells (via IL12), a lack of mature DCs could account for the down 
regulation of CD4, CD3, and CD8 genes and the lack of IL4 and IL17 
amplification in our study.  
Similarly, a study of DCs in peripheral blood in a small group of HCV 
recurrent patients found a transient decrease seven days after liver 
transplantation in the relative and absolute number of blood plasmacytoid DCs in 
both HCV and non-HCV infected patients (51). A similar trend was also found in 
the relative number of myeloid DCs. Researchers believe this incident could be 
due to the use of immunosuppressive drugs administered after transplantation. 
However, immunosuppressive drugs are known not only to affect DCs but also T 
cells as well.  
When examining the risk factors associated with accelerated fibrosis 
development in HCV recurrent patients post-LT, the role of immunosuppression 
is of particular interest because it is the only factor that can be modified (67). Two 
immunosupressants used on the patients in our study – cyclosporine and 
tacrolimus – are inhibitors of calcineurin, a protein phosphatase that activates the 
expression of IL2, which in turn stimulates the growth and differentiation of T 
cells. This diminishing effect of CNIs on the adaptive immune system may 
contribute to the universal recurrence of HCV infection, the accelerated 
progression of fibrosis (67), and could possibly account for the down regulation of 
T cell related genes and the lack of IL2 amplification in our study.  
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The presence of B cells was also examined by analysis of the CD19 
encoding gene, as a specific cell population marker, in differential fibrosis 
progression in HCV recurrent patients. Interestingly, no specific amplification was 
observed for CD19 throughout all analyzed biopsy samples. These results could 
potentially be explained by recent evidence that suggests that peripheral blood 
mononuclear cells, such as B cells, T cells, macrophages, and monocytes could 
also be potential reservoirs for the HCV replication (68). A study by Zehender et 
al (69) also confirmed the significant presence of HCV RNA in CD19+ peripheral 
blood mononuclear cells in patients with chronic HCV. If B cells and T cells are 
sites of HCV replication, this could explain a down regulation in T cell related 
genes and the absence of CD19 amplification in our results.    
Little is known regarding the specific pathogenesis of HCV recurrence 
disease. For immunocompetent patients, the gold standard for hepatic fibrosis 
assessment of and disease progression, post-LT, is liver biopsy. However, this 
costly and painful procedure is invasive and has been known to have serious, 
though infrequent, complications such as internal bleeding (7). Furthermore, liver 
function tests lack the sensitivity and specificity disease severity (63). Therefore, 
the development of biomarkers for identifying patients at a higher risk for 
developing accelerated fibrosis could be a very useful clinical tool (7). Presently, 
there are no means to predict patients at risk for accelerated fibrosis 
development (63). Our study, to the best of our knowledge, is the first study to 
demonstrate that gene expression analysis of CD4, near the time of HCV 
recurrence, could be used to predict accelerated fibrosis progression in HCV 
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recurrent patients. These findings could have significant clinical implications. The 
ability to identify patients at higher risk of accelerated fibrosis development could 
lead to earlier administration of antiviral therapy. It also could potentially help 
clinicians regulate immunosuppression therapy to ensure an adequate CD4+ T 
cell presence is available to help resolve HCV infection.  
In conclusion, the present study demonstrated that HCV recurrent patients 
who developed severe fibrosis 36 months post-LT showed a borderline 
significant down regulation in CD4 gene expression at the time of HCV 
recurrence (p = 0.052). This down-regulation of CD4 is consistent with other 
studies that show a weakened CD4 T cell response in chronic HCV patients. 
Gene expression analysis of CD4 early on in patients with HCV recurrence could 
potentially aid in identifying patients with greater risks for accelerated fibrosis 
development, allowing clinicians to regulate both antiviral and 
immunosuppression therapy. However, we recommend that further studies of 
CD4 expression in HCV recurrent patients be done, using a larger population of 
patients.  
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